NO20014314L - Blandinger og metoder for behandling av stafylokokkisk infeksjon - Google Patents

Blandinger og metoder for behandling av stafylokokkisk infeksjon

Info

Publication number
NO20014314L
NO20014314L NO20014314A NO20014314A NO20014314L NO 20014314 L NO20014314 L NO 20014314L NO 20014314 A NO20014314 A NO 20014314A NO 20014314 A NO20014314 A NO 20014314A NO 20014314 L NO20014314 L NO 20014314L
Authority
NO
Norway
Prior art keywords
compositions
treatment
methods
staphylococcal infection
staphylococcal
Prior art date
Application number
NO20014314A
Other languages
English (en)
Other versions
NO20014314D0 (no
Inventor
Michael Climo
Ellen Murphy
Gordon Archer
Original Assignee
Nutrition 21
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrition 21 filed Critical Nutrition 21
Publication of NO20014314D0 publication Critical patent/NO20014314D0/no
Publication of NO20014314L publication Critical patent/NO20014314L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24075—Lysostaphin (3.4.24.75)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20014314A 1999-03-05 2001-09-05 Blandinger og metoder for behandling av stafylokokkisk infeksjon NO20014314L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/263,776 US6569830B1 (en) 1999-03-05 1999-03-05 Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
PCT/US2000/005464 WO2000051588A1 (en) 1999-03-05 2000-03-03 Compositions and methods for treatment of staphylococcal infection

Publications (2)

Publication Number Publication Date
NO20014314D0 NO20014314D0 (no) 2001-09-05
NO20014314L true NO20014314L (no) 2001-10-11

Family

ID=23003182

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014314A NO20014314L (no) 1999-03-05 2001-09-05 Blandinger og metoder for behandling av stafylokokkisk infeksjon

Country Status (14)

Country Link
US (4) US6569830B1 (no)
EP (1) EP1181011A4 (no)
JP (1) JP2002538108A (no)
KR (1) KR20020010893A (no)
CN (1) CN1353602A (no)
AR (1) AR022791A1 (no)
AU (1) AU780864B2 (no)
BR (1) BR0008779A (no)
CA (1) CA2362487A1 (no)
IL (1) IL145282A0 (no)
NO (1) NO20014314L (no)
PL (1) PL364875A1 (no)
WO (1) WO2000051588A1 (no)
ZA (1) ZA200108215B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
GB0212622D0 (en) * 2002-05-31 2002-07-10 Natural Technologies Group Ltd Bacterial transforming agent
EP1567868A4 (en) * 2002-12-02 2008-02-06 Biosynexus Inc CELL WALL TEICHONSURE AS A GOAL F RANTI-STAPHYLOCOCCUS THERAPIES AND VACCINATES
ATE509018T1 (de) * 2004-01-23 2011-05-15 Nereus Pharmaceuticals Inc Als antimikrobielle mittel geeignete bisindolpyrrole
US7522663B2 (en) * 2005-03-10 2009-04-21 Stmicroelectronics, Inc. Burst error limiting feedback equalizer system and method for multidimensional modulation systems
WO2007008618A2 (en) * 2005-07-13 2007-01-18 University Of South Carolina Sterilization using high-pressure carbon dioxide
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
US20080015833A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for molecular inhibition of protein misfolding
US20080014572A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for molecular inhibition
US20080015835A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for treating disease
US20090082344A1 (en) * 2006-07-13 2009-03-26 Searete Llc Methods and systems for treating disease
GB0714029D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
WO2009114520A2 (en) * 2008-03-10 2009-09-17 Pharmain Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
WO2009152298A1 (en) * 2008-06-13 2009-12-17 Zeus Scientific, Inc. Methods, compositions and and diagnostic kits for the detection and treatment for staphylococcal nasal decolonization using achromopeptidase
SI2387580T1 (sl) 2009-01-14 2014-11-28 Novacta Biosystems Limited Deoksiaktagardinski derivati
MX2011008043A (es) 2009-02-04 2011-08-17 Novacta Biosystems Ltd Derivados de actagardina.
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
EP2916653A4 (en) 2012-11-01 2016-07-27 Univ Chicago ANTIBIOTIC PROCEDURES AND COMPOSITIONS FOR BACTERIAL INFECTIONS
US20150182605A1 (en) * 2013-12-28 2015-07-02 StaphRx, LLC Ultra-Low Dose Lysostaphin for Treating MRSA
WO2015175774A1 (en) 2014-05-14 2015-11-19 Trustees Of Dartmouth College Deimmunized lysostaphin and methods of use
EP3648740A1 (en) 2017-07-07 2020-05-13 EpicentRx, Inc. Compositions for parenteral administration of therapeutic agents
US20250144187A1 (en) * 2023-10-16 2025-05-08 Centre for Eye and Vision Research Limited Combination of hydrolases and anti-microorganism drugs and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278378A (en) 1962-04-19 1966-10-11 Schindler Charles Alvin Staphylococcus-derived antibiotic
US3398056A (en) 1964-07-10 1968-08-20 Mead Johnson & Co Process for producing lysostaphin by fermentation
US3594284A (en) 1968-06-04 1971-07-20 Mead Johnson & Co Lysostaphin fermentation with accelerated time cycle
US4931390A (en) 1986-04-16 1990-06-05 Public Health Research Institute Of The City Of New York, Inc. Expression of the cloned lysostaphin gene
US5858962A (en) * 1987-05-11 1999-01-12 Ambi Inc. Composition for treating mastitis and other staphylococcal infections
US5304540A (en) 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
AU623864B2 (en) 1988-08-29 1992-05-28 Applied Microbiology, Inc Method of treating mastitis and other staphylococcal infections
JPH0645553B2 (ja) * 1988-09-19 1994-06-15 アプライド マイクロバイオロジィ，インコーポレイテッド 乳房炎およびその他のブドウ球菌感染症の治療法並びに同治療用組成物
US5466685A (en) 1993-05-13 1995-11-14 Johnson & Johnson Inhibition of expression of beta-lactamase using esters of fatty acid alcohols
US6028051A (en) 1997-07-23 2000-02-22 Ambi Inc. Method for the treatment of staphylococcal disease
IL134056A0 (en) * 1997-07-23 2001-04-30 Ambi Inc Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains

Also Published As

Publication number Publication date
AR022791A1 (es) 2002-09-04
US8198231B2 (en) 2012-06-12
US6569830B1 (en) 2003-05-27
AU780864B2 (en) 2005-04-21
KR20020010893A (ko) 2002-02-06
ZA200108215B (en) 2006-03-29
EP1181011A1 (en) 2002-02-27
US20060246055A1 (en) 2006-11-02
US7078377B1 (en) 2006-07-18
PL364875A1 (en) 2004-12-27
IL145282A0 (en) 2002-06-30
WO2000051588A1 (en) 2000-09-08
AU3249000A (en) 2000-09-21
US20030199432A1 (en) 2003-10-23
CA2362487A1 (en) 2000-09-08
EP1181011A4 (en) 2003-05-21
CN1353602A (zh) 2002-06-12
JP2002538108A (ja) 2002-11-12
NO20014314D0 (no) 2001-09-05
US7122514B2 (en) 2006-10-17
BR0008779A (pt) 2002-10-15

Similar Documents

Publication Publication Date Title
NO20014314L (no) Blandinger og metoder for behandling av stafylokokkisk infeksjon
NO20024610D0 (no) Synergistiske metoder og blandinger for behandling av kreft
NO20025204L (no) Forbindelser og fremgangsmåter for behandling og forebygging av bakteriellinfeksjon
NO20015464L (no) Attenuerte mikroorganismer for behandling av infeksjon
NO20005017L (no) Metoder og viskøse sammensetninger for behandling av brønner
NO20015542L (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
NO20015516L (no) Preparater og anvendelser av ET743 for behandling av kreft
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20015772L (no) Forbindelser og fremgangsmåter for behandling av post- traumatisk stress-syndrom
NO20024777D0 (no) Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20024776L (no) Hydroksyfenyl-piperazinyl-metyl-benzamid derivater til behandling av smerte
NO20010464D0 (no) Fremgangsmåter og sammensetninger for behandling av gastroösofrageal-reflukssyndrom
NO20020784D0 (no) Medikament for behandling av brudd
NO20023737D0 (no) Fremgangsmåte og preparater for behandling av en inflammatorisk lidelse
NO20013651D0 (no) Anvendelse av fosfororganiske forbindelser for profylaktisk og terapeutisk behandling av infeksjoner
NO20001758D0 (no) Fremgangsmåter og blandinger for behandling av leddgikt
NO20020369L (no) Sammensetninger for forebyggelse og behandling av nyredysfunksjoner og -sykdommer
EP1233967A4 (en) PYRIDINONES FOR THE TREATMENT AND PREVENTION OF BACTERIAL INFECTIONS
NO20022949D0 (no) Attenuerte mikroorganismer for behandling av infeksjon
NO20014988D0 (no) Pseudomycinantisoppsammensetninger og fremgangsmåter for anvendelser av disse
NO20022990D0 (no) Fremgangsmåte og sammensetning for behandling av smerte
NO20013464D0 (no) Anvendelse av 3-isoksazolidinoner og hydroksylaminsyrer for behandling av infeksjoner
NO991827D0 (no) FremgangsmÕte for behandling av Streptococcus pneumoniae infeksjon
NO20014476L (no) Behandling av hiatial hernia
DK1105101T3 (da) Fremgangsmåder og præparater til behandling af intracellulære infektioner